This study is testing a new treatment for advanced or metastatic Merkel cell carcinoma, a type of skin cancer. It combines a drug called IFx-Hu2.0 with an existing immunotherapy drug, pembrolizumab. You would receive either IFx-Hu2.0 or a placebo (an inactive substance) injected directly into a tumor, followed by pembrolizumab given through an IV. The researchers want to see how many people respond to the treatment, specifically if their tumors shrink or disappear, which will be checked at 12 weeks and again at least 28 days later. To join, you must be at least 18 years old, have a life expectancy of at least six months, and have advanced or metastatic Merkel cell carcinoma that has come back or cannot be removed by surgery. The study is currently recruiting 118 participants.

Study design

This is a Phase 2/3, randomized, double-blind, placebo-controlled study involving 118 participants. This means participants are randomly assigned to receive either the study drug or a placebo, and neither you nor your doctors will know which you are receiving.

What's involved

You would receive injections of IFx-Hu2.0 or placebo into a tumor, followed by intravenous (IV) infusions of pembrolizumab. Your response to treatment will be assessed at 12 weeks and again at least 28 days later.

Compensation

Not stated in the trial record.

Follow-up

Your response to treatment will be assessed at 12 weeks after starting treatment and confirmed on a second assessment at least 28 days later.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.